Page last updated: 2024-11-05

trihexyphenidyl and Kernicterus

trihexyphenidyl has been researched along with Kernicterus in 1 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Kernicterus: A term used pathologically to describe BILIRUBIN staining of the BASAL GANGLIA; BRAIN STEM; and CEREBELLUM and clinically to describe a syndrome associated with HYPERBILIRUBINEMIA. Clinical features include athetosis, MUSCLE SPASTICITY or hypotonia, impaired vertical gaze, and DEAFNESS. Nonconjugated bilirubin enters the brain and acts as a neurotoxin, often in association with conditions that impair the BLOOD-BRAIN BARRIER (e.g., SEPSIS). This condition occurs primarily in neonates (INFANT, NEWBORN), but may rarely occur in adults. (Menkes, Textbook of Child Neurology, 5th ed, p613)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Appendino, JP1
Soman, T1

Other Studies

1 other study available for trihexyphenidyl and Kernicterus

ArticleYear
Correspondence on "Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy".
    Journal of child neurology, 2008, Volume: 23, Issue:7

    Topics: Adolescent; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dystonia; Humans; Ker

2008